DE69534718D1 - Substituierte 9-alkyladenine - Google Patents

Substituierte 9-alkyladenine

Info

Publication number
DE69534718D1
DE69534718D1 DE69534718T DE69534718T DE69534718D1 DE 69534718 D1 DE69534718 D1 DE 69534718D1 DE 69534718 T DE69534718 T DE 69534718T DE 69534718 T DE69534718 T DE 69534718T DE 69534718 D1 DE69534718 D1 DE 69534718D1
Authority
DE
Germany
Prior art keywords
alkyladenine
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69534718T
Other languages
English (en)
Other versions
DE69534718T2 (de
Inventor
V Peck
J Wysocki
M Uwaydah
J Cusack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aderis Pharmaceuticals Inc
Original Assignee
Aderis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aderis Pharmaceuticals Inc filed Critical Aderis Pharmaceuticals Inc
Publication of DE69534718D1 publication Critical patent/DE69534718D1/de
Application granted granted Critical
Publication of DE69534718T2 publication Critical patent/DE69534718T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69534718T 1994-09-01 1995-08-22 Substituierte 9-alkyladenine Expired - Fee Related DE69534718T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/299,992 US5670501A (en) 1994-09-01 1994-09-01 N-substituted 9-alkyladenines
US299992 1994-09-01
PCT/US1995/010693 WO1996006845A1 (en) 1994-09-01 1995-08-22 Substituted 9-alkyladenines

Publications (2)

Publication Number Publication Date
DE69534718D1 true DE69534718D1 (de) 2006-02-02
DE69534718T2 DE69534718T2 (de) 2006-09-07

Family

ID=23157204

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69534718T Expired - Fee Related DE69534718T2 (de) 1994-09-01 1995-08-22 Substituierte 9-alkyladenine

Country Status (6)

Country Link
US (2) US5670501A (de)
EP (2) EP1602657A3 (de)
JP (1) JPH10507744A (de)
AU (1) AU706068B2 (de)
DE (1) DE69534718T2 (de)
WO (1) WO1996006845A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10512896A (ja) * 1995-11-14 1998-12-08 フアルマシア・エ・アツプジヨン・エツセ・ピー・アー アリールおよびヘテロアリールプリン化合物
US7732484B2 (en) * 2000-08-01 2010-06-08 University Of Virginia Patent Foundation Use of selective adenosine A1 receptor allosteric enhancers to manipulate angiogenesis
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
ITRM20010465A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
WO2003050241A2 (en) 2001-12-12 2003-06-19 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
DE60204229T2 (de) * 2002-12-02 2006-02-02 Schwarz Pharma Ag Verabreichung von Rotigotine zur Behandlung der Parkinson'schen Krankheit durch Iontophorese
JP2008534445A (ja) * 2005-03-11 2008-08-28 アデリス ファーマシューティカルズ， インコーポレイテッド 置換９−アルキルアデニンおよびその使用
US7870903B2 (en) * 2005-07-13 2011-01-18 Halliburton Energy Services Inc. Inverse emulsion polymers as lost circulation material
KR100869259B1 (ko) 2007-05-29 2008-11-18 한국화학연구원 광학활성을 갖는 3ａ-메틸-피롤로[3,4-ｃ]피페리딘의거울상 이성질체의 제조방법
MX2015006191A (es) 2012-11-16 2015-08-10 Merck Sharp & Dohme Inhibidores de purina de fosfatidilinositol 3-quinasa delta humana.
JP6322200B2 (ja) * 2012-11-16 2018-05-09 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ヒトホスファチジルイノシトール３−キナーゼデルタのプリン阻害剤
US20190358262A1 (en) 2016-12-03 2019-11-28 Juno Therapeutics, Inc. Methods for modulation of car-t cells
US20200078400A1 (en) 2016-12-03 2020-03-12 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
MA46998A (fr) 2016-12-05 2019-10-09 Juno Therapeutics Inc Production de cellules modifiées pour une thérapie cellulaire adoptive
CN111225675B (zh) 2017-06-02 2024-05-03 朱诺治疗学股份有限公司 使用过继细胞疗法治疗的制品和方法
EP3644721A1 (de) 2017-06-29 2020-05-06 Juno Therapeutics, Inc. Mausmodell zur auswertung von toxizitäten im zusammenhang mit immunotherapien
HUE070649T2 (hu) 2017-10-19 2025-06-28 Teijin Pharma Ltd Benzimidazol-származékok és felhasználásuk
MX2020004572A (es) 2017-11-01 2020-10-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos.
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
CA3080904A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
KR20200116081A (ko) 2017-12-01 2020-10-08 주노 쎄러퓨티크스 인코퍼레이티드 유전자 조작된 세포의 투약 및 조절 방법
WO2019118937A1 (en) 2017-12-15 2019-06-20 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
MX2021005022A (es) 2018-11-01 2021-09-08 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
EP3880238A1 (de) 2018-11-16 2021-09-22 Juno Therapeutics, Inc. Verfahren zur dosierung von manipulierten t-zellen zur behandlung von b-zell-malignitäten
BR112021010354A2 (pt) 2018-11-30 2021-11-03 Juno Therapeutics Inc Métodos para o tratamento usando terapia celular adotiva
CA3123303A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
IL297147B1 (en) 2020-04-10 2026-05-01 Juno Therapeutics Inc Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
CN120051298A (zh) 2022-08-05 2025-05-27 朱诺治疗学股份有限公司 Gprc5d和bcma特异性嵌合抗原受体
WO2024129778A2 (en) 2022-12-13 2024-06-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2338705A1 (de) * 1973-07-31 1975-02-13 Boehringer Mannheim Gmbh Neue n(6)-disubstituierte adenosinderivate und verfahren zur herstellung derselben
DE2355536A1 (de) * 1973-11-07 1975-05-22 Merck Patent Gmbh Adeninderivate und verfahren zu ihrer herstellung
US4364922A (en) * 1980-10-14 1982-12-21 University Of Virginia Alumni Patents Foundation Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
US4612315A (en) * 1984-10-26 1986-09-16 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active 1,3-dipropyl-8-phenylxanthine derivatives
US4714697A (en) * 1985-09-09 1987-12-22 Warner Lambert Company N6 -bicycloadenosines and methods of use
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
DE3529497A1 (de) * 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US5565566A (en) * 1987-04-24 1996-10-15 Discovery Therapeutics, Inc. N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5066655A (en) * 1987-04-24 1991-11-19 Whitby Research, Inc. N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists
US4980379A (en) * 1988-06-30 1990-12-25 The University Of Virginia Use of adenosine antagonists in the treatment of bradyarrhythmias and hemodynamic depression associated with cardiopulmonary resucitation and/or cardiovascular collapse
WO1990009178A1 (en) * 1989-01-31 1990-08-23 Whitby Research, Inc. N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5117830A (en) * 1990-11-08 1992-06-02 Whitby Research, Inc. Method of determining viability of tissue
CA2060138A1 (en) * 1991-01-29 1992-07-30 Youichi Shiokawa New use of the adenosine antagonist

Also Published As

Publication number Publication date
EP0778836A1 (de) 1997-06-18
EP1602657A3 (de) 2006-11-15
DE69534718T2 (de) 2006-09-07
JPH10507744A (ja) 1998-07-28
EP0778836A4 (de) 1998-02-04
EP0778836B1 (de) 2005-12-28
US5981524A (en) 1999-11-09
AU706068B2 (en) 1999-06-10
AU3370695A (en) 1996-03-22
US5670501A (en) 1997-09-23
WO1996006845A1 (en) 1996-03-07
EP1602657A2 (de) 2005-12-07

Similar Documents

Publication Publication Date Title
FI954008L (fi) Substituoituja bifenyyli-isoksatsolisulfoniamideja
FI951908A7 (fi) Substituoituja pyridyylipyratsoleja
FI955927A7 (fi) Substituoidut 1H-imidatsolit
ATA166795A (de) Bis-resorcinyltriazine
ATA147195A (de) Alkoxyphenyl-substituierte bisbenzoylphosphinoxide
ATA163695A (de) 2-hydroxyphenyltriazine
ATA108995A (de) Differenzdruckakkumulator
BR9509559A (pt) Azolilulsolfonilfeniluracilas substituídas
ATA11894A (de) Stauförderbahn
DE59510274D1 (de) Substituierte biphenyloxazoline
ATE197372T1 (de) Vorteig
FI2105U1 (fi) Glaskrossanordning
FI1409U1 (fi) Vattenupplyftare
BR9400078A (pt) Emergensos
ATA127394A (de) Holografischer neurochip
BR7401146U (pt) Translixo
BR9403759A (pt) Mastercalc
BR7400062U (pt) Prato-bandeja
BR9403758A (pt) Multiplic
BR9401966A (pt) Intervalômetro-foto ARJ-07
BR7400242U (pt) Tele-comando
BR9403990A (pt) Quandriciclo ciclo-car
BR9401864A (pt) Pescoço-giratório
BR7400879U (pt) Boxboy
BR7400865U (pt) Multi-arremate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee